Tianjin Pharmaceutical Da Ren Tang Group Balance Sheet Health
Financial Health criteria checks 5/6
Tianjin Pharmaceutical Da Ren Tang Group has a total shareholder equity of CN¥6.3B and total debt of CN¥1.1B, which brings its debt-to-equity ratio to 16.9%. Its total assets and total liabilities are CN¥11.9B and CN¥5.6B respectively. Tianjin Pharmaceutical Da Ren Tang Group's EBIT is CN¥799.1M making its interest coverage ratio -3.3. It has cash and short-term investments of CN¥3.5B.
Key information
16.9%
Debt to equity ratio
CN¥1.07b
Debt
| Interest coverage ratio | -3.3x |
| Cash | CN¥3.51b |
| Equity | CN¥6.31b |
| Total liabilities | CN¥5.59b |
| Total assets | CN¥11.90b |
Recent financial health updates
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet
Jul 05
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet
Mar 18Recent updates
Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio
Jul 26Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet
Jul 05Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)
Apr 18Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet
Mar 18Financial Position Analysis
Short Term Liabilities: 600329's short term assets (CN¥8.2B) exceed its short term liabilities (CN¥5.2B).
Long Term Liabilities: 600329's short term assets (CN¥8.2B) exceed its long term liabilities (CN¥340.3M).
Debt to Equity History and Analysis
Debt Level: 600329 has more cash than its total debt.
Reducing Debt: 600329's debt to equity ratio has increased from 1.2% to 16.9% over the past 5 years.
Debt Coverage: 600329's debt is well covered by operating cash flow (105%).
Interest Coverage: 600329 earns more interest than it pays, so coverage of interest payments is not a concern.